Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs
Clinical trials sponsored by Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori Irst S.r.l. Irccs, explained in plain language.
-
Gentler vs stronger: major trial tests new hope for tough blood cancer
Disease control Recruiting nowThis large, late-stage trial aims to find out if newer, gentler personalized treatments work as well as or better than strong chemotherapy for adults whose acute myeloid leukemia (AML) has returned or hasn't responded to initial treatment. It will directly compare these two appro…
Phase: PHASE3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Mar 30, 2026 14:27 UTC
-
New Two-Pronged attack on spreading prostate cancer
Disease control Recruiting nowThis study is testing if a two-part treatment works better than one to control prostate cancer that has spread to a few spots. Men with 1-3 small metastases will receive either targeted radiotherapy alone or radiotherapy plus a targeted radioactive drug called Lu-PSMA. The goal i…
Phase: PHASE2 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Mar 11, 2026 14:53 UTC
-
Massive 4000-Patient study launches to map the fight against tough blood cancer
Knowledge-focused Recruiting nowThis study aims to collect real-world data on how patients with acute myeloid leukemia (AML) that has returned or is resistant to treatment fare across Europe. It will follow 4000 patients to understand survival rates, treatment responses, and which therapies are used in practice…
Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Mar 31, 2026 12:12 UTC